Abstract
BackgroundThis study aims to investigate the expression of thioredoxin 1, peroxiredoxin 1 and peroxiredoxin 2 in bulky cervical squamous carcinoma and its predictive role in cisplatin-based neoadjuvant chemotherapy.MethodsInitially, the expression of thioredoxin 1, peroxiredoxin 1 and peroxiredoxin 2 protein was analyzed in 13 human cervical squamous cancer tissues and their paired adjacent non-cancerous tissues by western-blotting and immunohistochemistry. Then, correlation between the expression of thioredoxin 1, peroxiredoxin 1, peroxiredoxin 2 and responses to cisplatin-based neoadjuvant chemotherapy was analyzed in 35 paired tumor samples (pre- and post-chemotherapy) from bulky cervical squamous cancer patients by immunohistochemistry.ResultsA clinical response occurred in 48.6% (17/35) of patients, including 14.3% (5/35) with a complete response and 34.3% (12/35) with a partial response. The expression of thioredoxin 1, peroxiredoxin 1 and peroxiredoxin 2 was much higher in cervical squamous cancer tissues compared with paired adjacent non-cancerous tissues by western-blotting and immunohistochemistry. Additionally, the expression of thioredoxin 1, peroxiredoxin 1 and peroxiredoxin 2 was significantly up-regulated in post-chemotherapy tissues compared to pre-chemotherapy cervical cancer tissues. High levels of thioredoxin 1, peroxiredoxin 1 and peroxiredoxin 2 were associated with a poor chemotherapy response in cervical squamous cancer patients.ConclusionsThioredoxin 1, peroxiredoxin 1 and peroxiredoxin 2 are frequently over-expressed in cervical squamous cancer. High expression levels of these proteins were related to a poor response to cisplatin-based neoadjuvant chemotherapy. The present study is the first report that thioredoxin peroxidase system may serve as a prediction of the responses to neoadjuvant chemotherapy in cervical squamous cancer.
Highlights
This study aims to investigate the expression of thioredoxin 1, peroxiredoxin 1 and peroxiredoxin 2 in bulky cervical squamous carcinoma and its predictive role in cisplatin-based neoadjuvant chemotherapy
Thioredoxin 1, peroxiredoxin 1/ 2 are overexpressed in cervical squamous cancer
High levels of thioredoxin 1 and peroxiredoxin 1/2 related to a poor chemotherapy response in cervical squamous cancer patients. * Correspondence: zxj1022@163.com; zjwzzxq@163.com †Haiyan Zhu and Xuejiao Tao contributed to this work. 2Department of Gynecology, the First Affiliated Hospital of Wenzhou Medical University, Shangcaicun Road, Wenzhou 325000, China 1Department of Obstetrics and Gynecology, the Second Affiliated Hospital of Wenzhou Medical University, No 109 Xueyuan Xi Road, Wenzhou 325027, Zhejiang, China
Summary
This study aims to investigate the expression of thioredoxin 1, peroxiredoxin 1 and peroxiredoxin 2 in bulky cervical squamous carcinoma and its predictive role in cisplatin-based neoadjuvant chemotherapy. Cervical cancer remains the second most commonly diagnosed cancer and third leading cause of cancer death among females in less developed countries, where a significant proportion of patients are diagnosed with locally advanced cervical cancer, and often have a poor prognosis [1]. Zhu et al BMC Cancer (2019) 19:865 to surgery has been widely used for bulky or locally advanced cervical cancer. In a large majority of these patients, treatment is effective, which can shrink the tumor size, suppress micrometastases, and promote the safety and integrity of surgery [2]. In 20–25% of cases, this neoadjuvant chemotherapy fails to achieve tumor regression [2], the prognosis of NACT-refractory patients would become worse due to the delay in curative treatment [3]. There is an obvious need to identify and develop novel biomarkers which may aid in predicting chemotherapy responses, and to assess the treatment options of individual patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
